Joseph Jurcic, MD

Joseph Jurcic, MD, professor of Clinical Medicine, director of the Hematologic Malignancies Section of the Hematology/Oncology Division, Columbia University Medical Center, discusses a phase I trial of lintuzumab and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML).

Joseph Jurcic, MD, head, Hematologic Malignancies, Columbia University Medical Center, discusses the next steps for research into radioimmunotherapy.